Skip to main content

Table 2 Best overall responses to nivolumab (n = 58)

From: Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study

Best overall response n (%)
Complete remission (CR) 0
Partial response (PR) 4 (7%)
Stable disease (SD) 17 (29%)
Progressive disease (PD) 37 (64%)
Objective response rate (ORR, CR + PR) 4 (7%)
Disease control rate (DCR, ORR + SD) 21 (36%)